Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 35,770 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $0.32, for a total value of $11,446.40. Following the sale, the director directly owned 107,429 shares of the company’s stock, valued at approximately $34,377.28. The trade was a 24.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, July 7th, Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $0.36 on Thursday. The firm has a market cap of $17.49 million, a price-to-earnings ratio of -0.29 and a beta of 0.30. Werewolf Therapeutics, Inc. has a one year low of $0.27 and a one year high of $2.38. The stock’s 50-day moving average is $0.45 and its 200 day moving average is $0.63.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HOWL. Regal Investment Advisors LLC grew its position in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Susquehanna International Group LLP raised its holdings in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings cut Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.